Dr. Hobar is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
No Street Address
Tampa, FL 33634
Summary
- Dr. Coburn Hobar is a rheumatologist based in Tampa, FL, specializing in lupus and related conditions. She completed a fellowship in rheumatology at the University of Tennessee and an Internal Medicine residency at the Virginia Commonwealth University Health System, after earning her medical degree from the McGovern Medical School at UTHealth. Her contributions to rheumatology include multiple publications in reputable journals such as Arthritis & Rheumatology, Annals of the Rheumatic Diseases, Lupus Science & Medicine, and Current Medical Research and Opinion. Her recent work focuses on clinical development in systemic lupus erythematosus, cutaneous lupus, and lupus nephritis.
Education & Training
University of TennesseeFellowship, Rheumatology, 2000 - 2002
Virginia Commonwealth University Health SystemResidency, Internal Medicine, 1997 - 2000
McGovern Medical School at UTHealthClass of 1997
Certifications & Licensure
FL State Medical License 2002 - 2020
Publications & Presentations
PubMed
- Plain Language Summary of the PAISLEY study: deucravacitinib as a treatment for people with systemic lupus erythematosus.Eric F Morand, Marilyn Pike, J Merrill, Ronald F van Vollenhoven, Victoria P Werth
Expert Opinion on Investigational Drugs. 2024-05-01 - 87 citationsDeucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.Eric Morand, Marilyn Pike, Joan T Merrill, Ronald van Vollenhoven, Victoria P Werth
Arthritis & Rheumatology. 2023-02-01 - 17 citationsInjection-site burning and stinging in patients with rheumatoid arthritis using injectable biologicsJeffrey R. Curtis, Coburn Hobar, Kevin Hansbrough
Current Medical Research and Opinion. 2011-01-01
Abstracts/Posters
- EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYK2 INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 2, RANDOMIZED, DOU...E Morand, M Pike, JT Merrell, R van Vollenhoven, VP Werth, C Hobar, N Delev, V Shah, B Sharkey, T Wegman, I Catlett, S Bannerjee, S Singhal, Annals of the Rheumatic Diseases, EULAR 2022, 6/4/2022
- Oral selective tyrosine kinase 2 (TYK2) inhibition with BMS-986165 in patients with systemic lupus erythematosus: a phase 2, randomized, double-blind, placebo-controll...Singhal S, Shah V, Crater C, Hobar C, Nguyen H, Throup J, Banerjee S, Merrill JT, Lupus Science & Medicine 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
